


**IN THE CLAIMS**



This listing of claims replaces all prior versions, and listings, in this application.

Claim 1 (canceled)

2. (currently amended) The compound according to claim 25, wherein:



and



3. (previously presented) The compound according to claim 2, wherein:

R<sub>1</sub> and R<sub>2</sub> are selected from the group consisting of aminoethyl, anilino, 1,3-dihydroxy-2-propyl, and hydroxyethyl; and

R<sub>3</sub> is selected from the group consisting of aminoethyloxyethyl, aminophenethyl, anilino, bis(hydroxyethyl), and bis(hydroxyethyl)aminoethyl.

4. (previously presented) The compound according to claim 3, wherein:

R<sub>1</sub> is selected from the group consisting of 1,3-dihydroxy-2-propyl and hydroxyethyl;  
and


R<sub>2</sub> is selected from the group consisting of anilino and 1,3-dihydroxy-2-propyl.

5. (previously presented) A compound selected from the group consisting of:


**Compound  
No.**

**Structure**


1



2




3




**Compound  
No.**

**Structure**


4



5




6




**Compound  
No.**

**Structure**


7



8



9




Compound

No.

Structure

10




11a


X = O

11b

X = S




12




**Compound  
No.**

**Structure**


13




14




15



16



17




| Compound<br>No.                       | Structure |
|---------------------------------------|-----------|
| 18                                    |           |
| 19a X = OH<br>19b X = NH <sub>2</sub> |           |
| 20                                    |           |
| 21                                    |           |
| 22                                    |           |

**Compound**


**No.**

**Structure**


23




24



25



26






**Compound**


**No.**

**Structure**


27




28



29



30




**Compound**


**No.**

**Structure**


31




32



33




34




**Compound  
No.**

**Structure**


35



36




37




**Compound  
No.**

**Structure**


38




39



40




41




**Compound  
No.**

**Structure**


42




43



44




45




**Compound  
No.**

**Structure**


46




47




48



49



50




and

**Compound**

**No.**


**Structure**

51



6. (previously presented) The compound according to claim 25 which can noncovalently bind to antibodies.

7. (previously presented) The compound according to claim 25 which can noncovalently bind to antibodies, wherein one, two, or three of the substituents  $R_1$ ,  $R_2$ ,  $R_3$  is



8. (previously presented) The compound according to claim 6, wherein the antibodies are at least of the human IgG isotype.

9. (currently amended) A composition comprised of ~~at least one compound~~ one or more compound(s) according to claim 25, wherein said compound(s) is combined with a pharmaceutically acceptable carrier.

10. (original) The composition according to claim 9, wherein said carrier solubilizes said compound in an alcohol or polyol solvent.

11. (original) The composition according to claim 9 further comprised of a recombinant protein which is able to bind to human TNF $\alpha$ .

12. (original) The composition according to claim 11, wherein said recombinant protein is anti-TNF $\alpha$  antibody or soluble TNF $\alpha$  receptor.

13. (original) The composition according to claim 9 further comprised of methotrexate.

14. (original) The composition according to claim 9 further comprised of an anti-inflammatory corticosteroid.

15. (original) The composition according to claim 9 further comprised of a nonsteroidal anti-inflammatory drug.

16. (previously presented) A method of treating a patient with glomerulonephritis, psoriasis, rheumatoid arthritis, or systemic lupus erythematosus comprising administering a therapeutically effective amount of a compound according to claim 25 to said patient.

17. (previously presented) A method of treating a patient with glomerulonephritis, psoriasis, rheumatoid arthritis, or systemic lupus erythematosus comprising administering a therapeutically effective amount of a composition according to claim 9 to said patient, wherein said composition is further comprised of methotrexate, an anti-inflammatory corticosteroid, or a nonsteroidal anti-inflammatory drug.

18. (previously presented) A method of treating a patient with glomerulonephritis, psoriasis, rheumatoid arthritis, or systemic lupus erythematosus comprising administering a therapeutically effective amount of a composition according to claim 11 to said patient.

19. (previously presented) The method of claim 16 further comprising simultaneously administering a therapeutically effective amount of a recombinant protein which is able



to bind to human TNF $\alpha$ , wherein said therapeutically effective amount of recombinant protein is reduced in the presence of said compound.

20. (previously presented) The method of claim 16 further comprising separately administering therapeutically effective amount of a recombinant protein which is able to bind to human TNF $\alpha$  before and/or after administration of said compound, but not simultaneous administration.


21. (previously presented) A method of treating a mammal affected by inflammation, comprising administering a therapeutically effective amount of one or more compounds according to claim 25 to said mammal and thereby inhibiting TNF $\alpha$  proinflammatory activity or production.

22. (previously presented) A method of removal of human antibodies comprised of circulating blood or other physiological fluid through an apheresis column, wherein one or more compounds according to claim 25 are covalently linked either directly or with an organic linker to an insoluble support material which constitutes part of said apheresis column such that at least some free antibodies and/or antibody-antigen immune complexes are bound thereto; and returning at least some said blood or other physiological fluid, wherein at least some human antibodies have been removed therefrom, to a patient from whom said blood or other physiological fluid was obtained.



23. (previously presented) A method of purification of antibodies comprised of binding antibodies with one or more compounds according to claim 25 covalently linked either directly or with an organic linker to an insoluble support material such that at least some antibodies are noncovalently bound to said compounds linked to the insoluble support and purifying said antibodies.

24. (previously presented) A method of binding antibody using one or more compounds according to claim 25, comprised of incubating said one or more compounds to bind the antibody and then separating bound antibody from free antibody.

25. (currently amended) A compound of the following formula:





where  $A = (CH_2)_n$ ,  $n = 0, 1, 2$



where  $A = (CH_2)_n$ ,  $n = 0-2$ , or  
 $= (CH_2)_m$ ,  $m = 2-4$ ; and  
 $X = H, F$  or  $NH_2$

wherein  $R_1$ ,  $R_2$ , and  $R_3$  are independently selected from the group consisting of ~~N-~~acetylaniline,





C<sub>2-4</sub> aminoalkyl, aminoethoxyethyl, aminophenethyl, anilino, benzyl, bis(hydroxyethyl), bis(hydroxyethyl)aminoethyl, 1,3-dihydroxy-2-propyl, and fluorophenyl, C<sub>2-4</sub> hydroxyalkyl, hydroxyphenethyl, phenethyl, and phenyl.


26. (previously presented) A compound selected from the group consisting of:

**Compound**


**Structure**

**No.**


1



17



19a




**Compound**


**No.**

**Structure**


35




38



47




50




**Compound  
No.**

**Structure**


52




53




54



55




56




**Compound  
No.**

**Structure**


57




58




59




60



61




62



**Compound  
No.**

**Structure**

63



and

64

